Weisheit Attorneys Challenge Indiana Execution Over Drug Purity

Weisheit Attorneys Challenge Indiana Execution Over Drug Purity

by

Attorneys for Jeffrey Weisheit are petitioning Governor Mike Braun to halt an execution scheduled for before sunrise on Nov. 5, citing a lack of transparency regarding the quality of the lethal drugs intended for use. The legal challenge centers on whether the state of Indiana can prove that the pentobarbital it plans to administer is potent, pure, and has been stored under appropriate conditions.

The request for a temporary reprieve and an independent review of execution procedures follows Governor Braun’s recent decision to deny Weisheit’s plea to commute his death sentence to life without parole. Weisheit is currently facing execution at the Indiana State Prison in Michigan City for the 2010 murders of 8-year-old Alyssa Lynch and her 5-year-old brother, Caleb, in a house fire near Evansville.

Questions over drug potency and storage

The core of the supplemental filing submitted Tuesday involves the state’s recent procurement of pentobarbital, a supply that cost $275,000. While the Indiana Department of Correction confirmed Monday that the drugs are in its possession, the specific details regarding their integrity remain undisclosed. According to an inventory log released to the Indiana Capital Chronicle, the state received six 50-milliliter vials on Oct. 29.

However, the log lacks critical data points, including expiration dates, testing results, or temperature readings. This absence of documentation is a central point of contention for the defense. Attorneys for Weisheit argue that without verification of the drugs’ stability and purity, the state is bypassing standard medical and procedural safeguards.

Desktop hd charleston south carolina wallpaper

The legal team pointed to discrepancies in how Indiana manages its pharmaceutical inventory compared to other jurisdictions. For example, a 2017 settlement in Arizona requires state officials to provide an analysis of execution chemicals and their concentrations within 10 days of seeking a warrant. Similarly, a March 2025 affidavit from South Carolina’s corrections director documented the use of laboratory testing on pentobarbital prior to a scheduled execution.

“Indiana is singular in its apparent failure to conduct any testing to ensure the potency, purity, and stability of its execution drugs. This willfully disregards rudimentary practices,” attorney Joe Perkovich said in a news release.

The Department of Correction has not responded to inquiries regarding whether any efficacy testing has been performed on the new supply. Furthermore, previous public records requests obtained by the Indiana Capital Chronicle revealed that Department of Correction temperature logs had previously shown readings that fell outside the recommended storage range.

The role of the state’s pharmacy supplier

The legal scrutiny has also extended to Pharmaneek Inc., the Indianapolis-based pharmacy identified as the supplier for Indiana’s execution drugs. The pharmacy is currently under probation and is scheduled for a hearing on Nov. 9 regarding alleged violations of compounding restrictions. While the board has not yet ordered a suspension of the pharmacy’s operations, the timing of the hearing creates an additional layer of uncertainty surrounding the state’s supply chain.

The Indiana Department of Correction and the Indiana Attorney General’s office defended the state’s readiness on Monday. However, officials declined to provide specific details about the supplier, citing state confidentiality laws. This refusal to disclose information has left the defense to argue that the state is operating with a level of secrecy that precludes meaningful judicial oversight.

The outcome of the pending request for a reprieve will determine whether the scheduled execution proceeds as planned or if the state must first provide the requested documentation to satisfy the court’s concerns regarding the chemicals’ integrity.

Keep reading

Read next